Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 313
6
Diseases
33
Unique genes
0.116
Avg. similarity score
Hypertensive heart disease
Most-connected disease (4 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Hypertensive heart disease
Hydronephrosis
Hypertensive nephropathy
focal segmental glomerulosclerosis 4, susceptibility to
Kidney atrophy
Trichomegaly
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Hypertensive heart disease | 4 | 4 | 10 |
| Hydronephrosis | 2 | 2 | 12 |
| Hypertensive nephropathy | 2 | 2 | 20 |
| focal segmental glomerulosclerosis 4, susceptibility to | 2 | 2 | 1 |
| Kidney atrophy | 1 | 1 | 1 |
| Trichomegaly | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| APOL1 | 3 / 6 | focal segmental glomerulosclerosis 4, susceptibility to, Hypertensive heart disease, Hypertensive nephropathy |
| PDILT | 3 / 6 | Hydronephrosis, Hypertensive heart disease, Hypertensive nephropathy |
| C12ORF57 | 2 / 6 | Hydronephrosis, Kidney atrophy |
| DCDC1 | 2 / 6 | Hypertensive heart disease, Hypertensive nephropathy |
| FGF5 | 2 / 6 | Hypertensive heart disease, Trichomegaly |
| FTO | 2 / 6 | Hypertensive heart disease, Hypertensive nephropathy |
| PRKAG2 | 2 / 6 | Hypertensive heart disease, Hypertensive nephropathy |
| SCARB1 | 2 / 6 | Hypertensive heart disease, Hypertensive nephropathy |
| TCF7L2 | 2 / 6 | Hypertensive heart disease, Hypertensive nephropathy |
| UMOD | 2 / 6 | Hydronephrosis, Hypertensive heart disease |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | Reactome | 2 / 12 | 60.7× | 4.75e-4 | 7.66e-3 ✓ sig. |
| Scavenging of heme from plasma | Reactome | 2 / 13 | 56.0× | 5.60e-4 | 8.70e-3 ✓ sig. |
| RHO GTPases activate PAKs | Reactome | 2 / 23 | 31.6× | 1.79e-3 | 2.10e-2 ✓ sig. |
| Biosynthesis of EPA-derived SPMs | Reactome | 1 / 1 | 364× | 2.75e-3 | 2.89e-2 ✓ sig. |
| Biosynthesis of DPAn-3 SPMs | Reactome | 1 / 1 | 364× | 2.75e-3 | 2.89e-2 ✓ sig. |
| African trypanosomiasis | KEGG | 2 / 37 | 19.7× | 4.59e-3 | 4.14e-2 ✓ sig. |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | Reactome | 1 / 2 | 182× | 5.49e-3 | 4.65e-2 ✓ sig. |
| Reversal of alkylation damage by DNA dioxygenases | Reactome | 1 / 2 | 182× | 5.49e-3 | 4.65e-2 ✓ sig. |
| TCF7L2 mutants don't bind CTBP | Reactome | 1 / 3 | 121× | 8.22e-3 | 6.07e-2 |
| Biosynthesis of DHA-derived SPMs | Reactome | 1 / 3 | 121× | 8.22e-3 | 6.07e-2 |
| Abacavir transmembrane transport | Reactome | 1 / 3 | 121× | 8.22e-3 | 6.07e-2 |
| Cushing syndrome | KEGG | 3 / 155 | 7.0× | 8.66e-3 | 6.30e-2 |
| Ovarian steroidogenesis | KEGG | 2 / 52 | 14.0× | 8.91e-3 | 6.41e-2 |
| Neurotransmitter clearance | Reactome | 1 / 4 | 91.0× | 1.09e-2 | 7.25e-2 |
| Arachidonic acid metabolism | KEGG | 2 / 63 | 11.6× | 1.29e-2 | 7.94e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of blood pressure | GO:0008217 | 4 / 83 | 27.3× | 1.34e-5 | 6.57e-4 ✓ sig. |
| platelet aggregation | GO:0070527 | 3 / 49 | 34.7× | 8.75e-5 | 2.74e-3 ✓ sig. |
| cellular oxidant detoxification | GO:0098869 | 3 / 66 | 25.7× | 2.13e-4 | 5.27e-3 ✓ sig. |
| blood vessel endothelial cell migration | GO:0043534 | 2 / 13 | 87.1× | 2.33e-4 | 5.62e-3 ✓ sig. |
| fatty acid biosynthetic process | GO:0006633 | 3 / 82 | 20.7× | 4.04e-4 | 8.27e-3 ✓ sig. |
| prostaglandin biosynthetic process | GO:0001516 | 2 / 17 | 66.6× | 4.05e-4 | 8.28e-3 ✓ sig. |
| renal sodium ion absorption | GO:0070294 | 2 / 21 | 53.9× | 6.22e-4 | 1.11e-2 ✓ sig. |
| prostaglandin metabolic process | GO:0006693 | 2 / 30 | 37.8× | 1.28e-3 | 1.75e-2 ✓ sig. |
| high density lipoprotein particle mediated signaling | GO:0055097 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| regulation of protein sumoylation | GO:0033233 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| glomerular mesangial cell proliferation | GO:0072110 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| positive regulation of glomerular metanephric mesangial cell proliferation | GO:0072303 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| cellular response to interleukin-8 | GO:0098759 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| positive regulation of post-translational protein modification | GO:1901875 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
| regulation of membrane repolarization during atrial cardiac muscle cell action potential | GO:1905000 | 1 / 1 | 566× | 1.77e-3 | 2.11e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Hypertensive heart disease | Hypertensive nephropathy | 0.292 | 7 | 2.28e-19 | 4.42e-18 ✓ sig. |
| Hydronephrosis | Hypertensive heart disease | 0.095 | 2 | 2.50e-5 | 1.23e-4 ✓ sig. |
| focal segmental glomerulosclerosis 4, susceptibility to | Hypertensive heart disease | 0.091 | 1 | 6.49e-4 | 1.22e-3 ✓ sig. |
| Hypertensive heart disease | Trichomegaly | 0.091 | 1 | 6.49e-4 | 1.22e-3 ✓ sig. |
| Hydronephrosis | Kidney atrophy | 0.077 | 1 | 7.79e-4 | 1.39e-3 ✓ sig. |
| focal segmental glomerulosclerosis 4, susceptibility to | Hypertensive nephropathy | 0.048 | 1 | 1.30e-3 | 2.04e-3 ✓ sig. |